Perrigo (PRGO) Net Income towards Common Stockholders Growth (5y) (2017 - 2026)
Perrigo (PRGO) Net Income towards Common Stockholders Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Perrigo | 1.93 Bn | 1.53 Bn | 313.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -17.71% |
| Mar 28, 2026 | -17.57% |
| Dec 31, 2025 | 50.91% |
| Sep 27, 2025 | 50.83% |
| Jun 28, 2025 | -16.69% |
| Mar 29, 2025 | -16.36% |
| Dec 31, 2024 | 14.06% |
| Sep 28, 2024 | -15.29% |
| Jun 29, 2024 | -18.13% |
| Mar 30, 2024 | -15.24% |
| Dec 31, 2023 | -15.51% |
| Sep 30, 2023 | 55.33% |
| Jul 1, 2023 | -15.03% |
| Apr 1, 2023 | -15.14% |
| Dec 31, 2022 | -16.55% |
| Oct 1, 2022 | -42.90% |
| Jul 2, 2022 | 68.98% |
| Apr 2, 2022 | -15.05% |
| Dec 31, 2021 | 55.97% |
| Oct 2, 2021 | 68.41% |